Aspira Pathlab & Diagnostics (BOM:540788) EPS (Basic): ₹-0.00 (TTM As of Mar. 2026)


BOM:540788 Aspira Pathlab & Diagnostics Ltd BOM:540788
46 GF Score
Price ₹128.70
GF Value ₹69.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aspira Pathlab & Diagnostics EPS (Basic)?

Aspira Pathlab & Diagnostics BOM:540788 +1.78% 46 EPS (Basic) is ₹-0.00 as of Mar. 2026. GuruFocus rates BOM:540788 with a GF Score™ of 46/100 and a GF Value™ of ₹69.13 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Aspira Pathlab & Diagnostics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹-0.67. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.00.

Aspira Pathlab & Diagnostics's EPS (Diluted) for the three months ended in Mar. 2026 was ₹-0.67. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-0.00.

Aspira Pathlab & Diagnostics's EPS without NRI for the three months ended in Mar. 2026 was ₹-0.67. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.00.

During the past 12 months, Aspira Pathlab & Diagnostics's average EPS without NRIGrowth Rate was -97.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Aspira Pathlab & Diagnostics's highest 3-Year average EPS without NRI Growth Rate was 73.10% per year. The lowest was -37.70% per year. And the median was 2.00% per year.

Aspira Pathlab & Diagnostics  (BOM:540788) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Aspira Pathlab & Diagnostics EPS (Basic) Related Terms

Aspira Pathlab & Diagnostics EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Aspira Pathlab & Diagnostics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Pathlab & Diagnostics EPS (Basic) Chart

Aspira Pathlab & Diagnostics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.33 -0.09 -2.60 2.01 0.05

Aspira Pathlab & Diagnostics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 0.41 1.78 -1.52 -0.67
BOM:540788
46GF Score
Aspira Pathlab & Diagnostics Ltd BOM:540788
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aspira Pathlab & Diagnostics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Aspira Pathlab & Diagnostics's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(0.513-0)/10.260
=0.05

Aspira Pathlab & Diagnostics's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-6.891-0)/10.285
=-0.67

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹-0.00 mean?
Aspira Pathlab & Diagnostics (BOM:540788) has a EPS (Basic) of ₹-0.00 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aspira Pathlab & Diagnostics and its competitors.
Is Aspira Pathlab & Diagnostics' EPS (Basic) too high?
Aspira Pathlab & Diagnostics' current EPS (Basic) is ₹-0.00. Overall, Aspira Pathlab & Diagnostics has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Pathlab & Diagnostics' EPS (Basic) compare to TMO and DHR?
Aspira Pathlab & Diagnostics' EPS (Basic) of ₹-0.00 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aspira Pathlab & Diagnostics and its competitors. Aspira Pathlab & Diagnostics's current EPS (Basic) is ₹-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Pathlab & Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics (BOM:540788) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹69.13, compared to a current price of ₹128.70 — trading 86.2% above its estimated fair value. The current EPS (Basic) is ₹-0.00. Aspira Pathlab & Diagnostics' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Aspira Pathlab & Diagnostics (BOM:540788), the current EPS (Basic) is ₹-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Pathlab & Diagnostics (BOM:540788) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Pathlab & Diagnostics stock appears to be overvalued. The current stock price of ₹128.70 is trading 86.2% above its estimated GF Value™ of ₹69.13. GuruFocus considers Aspira Pathlab & Diagnostics to be Significantly Overvalued.

Key valuation signals for BOM:540788:

  • EPS (Basic): ₹-0.00
  • GF Value™: ₹69.13 vs. price of ₹128.70 (86.2% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the BOM:540788 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Pathlab & Diagnostics Business Description

Address 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (west), Mumbai, MH, IND, 400086
Aspira Pathlab & Diagnostics Ltd is mainly engaged in pathology and related healthcare services. It operates laboratories that conduct a wide range of pathological investigations across branches such as biochemistry, hematology, histopathology, microbiology, immunochemistry, immunology, virology, cytology, and other pathological and radiological tests. The services offered include pathology tests, sonography, X-rays, and radiology. The company also provides various health packages like gynecology profiles, anemia profiles, monsoon profiles, coagulation tests, cancer screening packages, newborn screening and IEM panels, orthopedic profiles, allergy panels, and cardiac profiles. These comprehensive diagnostic services assist in disease diagnosis.
46GF Score

Get the complete analysis for BOM:540788

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹128.70
Price
₹69.13
GF Value